Provided by Tiger Fintech (Singapore) Pte. Ltd.

NanoViricides

1.23
+0.02001.65%
Volume:181.96K
Turnover:224.03K
Market Cap:19.24M
PE:-1.72
High:1.28
Open:1.22
Low:1.19
Close:1.21
Loading ...

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

ACCESS Newswire
·
04 Mar

NanoViricides reports Q2 EPS (14c) vs. (18c) last year

TIPRANKS
·
19 Feb

NanoViricides, Inc. Has Filed its Quarterly Report

ACCESS Newswire
·
19 Feb

NanoViricides: Fiscal Q2 Earnings Snapshot

Associated Press Finance
·
15 Feb

Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?

Insider Monkey
·
15 Feb

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

ACCESS Newswire
·
11 Feb

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

ACCESS Newswire
·
29 Jan

NanoViricides Inc: Engages Cro for Phase Ii Clinical Trial

THOMSON REUTERS
·
27 Jan

NanoViricides Engages CRO for Phase II Clinical Trial

ACCESS Newswire
·
27 Jan

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

ACCESSWIRE
·
13 Jan

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

ACCESSWIRE
·
08 Jan

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

ACCESSWIRE
·
23 Dec 2024

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

ACCESSWIRE
·
15 Nov 2024

NanoViricides: Fiscal Q1 Earnings Snapshot

Associated Press Finance
·
15 Nov 2024

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

ACCESSWIRE
·
04 Nov 2024

NanoViricides President Dr. Diwan to Present at the PODD Conference

ACCESSWIRE
·
22 Oct 2024